Abstract
The 2014 year ended with celebration: Everolimus, a rapamycin analog, was shown to improve immunity in old humans, heralding "a turning point" in research and new era in human quest for immortality. Yet, this turning point was predicted a decade ago. But what will cause human death, when aging will be abolished?
Highlights
In 2003 it was proposed that activation of growthpromoting pathways should cause senescence, when the cell cycle is blocked [58]
All gerogenic pathways converge on the mTOR pathway: upstream and downstream [7783]
Independently, mTOR pathway was revealed in the studies of human diseases: Parkinson and Alzheimer, cancer and benign tumors, cardiac fibrosis and atherosclerosis, renal hypertrophy and diabetic complications [19, 88,89,90,91,92,93,94,95,96,97]
Summary
As announced by Lamming et al, “A growing list of side effects make it doubtful that rapamycin would be beneficial in humans.” [14] the same opponent re-invented mTOR-centric model (without appropriate reference), suggesting that “longevity is promoted not via increased insulin sensitivity, but instead via decreased PI3K/Akt/mTOR pathway signaling” [15]. As it was predicted in 2008 [4], opponents take mTOR-centric model for granted. More on that was discussed previously [16, 21,22,23,24,25,26,27]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
